NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $31.00 price objective on the stock.

NRXP has been the subject of several other research reports. Ascendiant Capital Markets boosted their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th.

NRx Pharmaceuticals Stock Down 5.4 %

NRXP opened at $1.94 on Monday. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $6.01. The business has a fifty day simple moving average of $2.50 and a 200-day simple moving average of $2.05. The firm has a market cap of $32.82 million, a P/E ratio of -0.91 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Sell-side analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Trading of NRx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. AdvisorShares Investments LLC boosted its position in shares of NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after acquiring an additional 180,229 shares in the last quarter. Anson Funds Management LP lifted its stake in NRx Pharmaceuticals by 30.3% during the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after purchasing an additional 43,135 shares during the last quarter. Millennium Management LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter valued at approximately $61,000. Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals in the fourth quarter valued at approximately $56,000. Finally, Townsquare Capital LLC acquired a new stake in NRx Pharmaceuticals during the third quarter worth approximately $25,000. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.